Literature DB >> 15330200

Association of K-ras mutations with liver metastases from colorectal carcinoma.

Akira Tsunoda1, Takeru Iijima, Yuko Tsunoda, Kentaroh Nakao, Michiko Miyaki, Mitsuo Kusano.   

Abstract

BACKGROUND: Colorectal carcinomas were studied regarding early proof of liver metastases through determination of K-ras mutations. PATIENTS AND METHODS: Seventy-seven colorectal carcinomas were investigated for the presence of point mutations in codon 12 and 13 of the K-ras gene, using single-strand conformation polymorphism (SSCP) analysis and direct sequencing.
RESULTS: Twenty-six carcinomas were positive for K-ras mutations, of which 21 had codon 12 and 5 had codon 13 mutations. Twenty patients with K-ras-positive tumor (20 out of 26: 77%) developed liver metastases, of which 13 had simultaneous metastases and 7 had metachronous metastases. There was a significant association between K-ras mutations and liver metastases (p=0.03). A multivariate logistic regression model demonstrated that the involvement of lymph node (p<0.01) and K-ras mutations (p=0.02) were predictive factors for liver metastases from colorectal carcinoma. Sequencing in carcinomas without liver metastases showed the base change in the first position of codon 12, whereas with liver metastases it showed significantly frequent base change in the second position of codon 12 (p<0.01).
CONCLUSION: It is suggested that the presence of K-ras mutation, especially base change in the second position of codon 12, may predict liver metastases from colorectal carcinoma.

Entities:  

Mesh:

Year:  2004        PMID: 15330200

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  3 in total

1.  Relationships between KRAS mutation status and baseline radiographic distribution of disease in patients with stage IV colorectal cancer.

Authors:  Michael H Rosenthal; Kyung Won Kim; Charles S Fuchs; Jeffrey A Meyerhardt; Nikhil H Ramaiya
Journal:  Abdom Imaging       Date:  2014-12

2.  High MACC1 expression in combination with mutated KRAS G13 indicates poor survival of colorectal cancer patients.

Authors:  Katharina Ilm; Wolfgang Kemmner; Marc Osterland; Susen Burock; Gudrun Koch; Pia Herrmann; Peter M Schlag; Ulrike Stein
Journal:  Mol Cancer       Date:  2015-02-14       Impact factor: 27.401

3.  KRAS-mutation incidence and prognostic value are metastatic site-specific in lung adenocarcinoma: poor prognosis in patients with KRAS mutation and bone metastasis.

Authors:  Zoltan Lohinai; Thomas Klikovits; Judit Moldvay; Gyula Ostoros; Erzsebet Raso; Jozsef Timar; Katalin Fabian; Ilona Kovalszky; István Kenessey; Clemens Aigner; Ferenc Renyi-Vamos; Walter Klepetko; Balazs Dome; Balazs Hegedus
Journal:  Sci Rep       Date:  2017-01-04       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.